Neuberger Berman Capital Solutions Completes Direct Investment in Worldwide Clinical Trials

Neuberger Berman Capital Solutions Completes Direct Investment in Worldwide Clinical Trials

New York, NY, December 12, 2023 - Neuberger Berman Capital Solutions ("NB Capital Solutions") is pleased to announce a strategic investment in Worldwide Clinical Trials ("Worldwide", the "Company"), alongside prominent private equity firm, Kohlberg & Company. Worldwide is a globally recognized contract research organization (CRO) that offers comprehensive services ranging from bioanalytical laboratory services to post-approval studies, with a focus on Phase I-IV clinical trials.

The investment by NB Capital Solutions will support Worldwide's mission to provide innovative and tailored solutions in the fields of neuroscience, oncology, rare diseases, as well as cardiometabolic and inflammatory diseases. Worldwide's extensive experience and personalized approach ensure the advancement of new medications from discovery to reality, benefiting patients worldwide.

"We are excited to partner with Kohlberg & Company to support Worldwide's continued growth and development in the biotechnology and pharmaceutical sectors," said J.T. Munch, Managing Director, NB Capital Solutions. "Our investment underscores our commitment to fostering innovation in the healthcare industry, and we are confident that Worldwide's expertise will lead to significant advancements in the development of new therapies."

Latham & Watkins LLP served as legal advisor to NB Capital Solutions.